China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its injectable SPN0103-009 for the treatment of type 2 diabetes and obesity.
Drug Profile
SPN0103-009 is a novel, long-acting GLP-1 peptide analog designed for improved stability, enabling weekly dosing. Preclinical animal tests demonstrated that SPN0103-009 exhibited superior pharmacokinetic parameters compared to semaglutide and was safe and well-tolerated.
Future Development
Sinopep-Allsino plans to further develop SPN0103-009 for non-alcoholic fatty liver disease (NASH) and Alzheimer’s disease, expanding its therapeutic applications beyond diabetes and obesity.-Fineline Info & Tech
